323 related articles for article (PubMed ID: 21326808)
1. NPM-ALK and the JunB transcription factor regulate the expression of cytotoxic molecules in ALK-positive, anaplastic large cell lymphoma.
Pearson JD; Lee JK; Bacani JT; Lai R; Ingham RJ
Int J Clin Exp Pathol; 2011 Jan; 4(2):124-33. PubMed ID: 21326808
[TBL] [Abstract][Full Text] [Related]
2. The heat shock protein-90 co-chaperone, Cyclophilin 40, promotes ALK-positive, anaplastic large cell lymphoma viability and its expression is regulated by the NPM-ALK oncoprotein.
Pearson JD; Mohammed Z; Bacani JT; Lai R; Ingham RJ
BMC Cancer; 2012 Jun; 12():229. PubMed ID: 22681779
[TBL] [Abstract][Full Text] [Related]
3. The oncoprotein NPM-ALK of anaplastic large-cell lymphoma induces JUNB transcription via ERK1/2 and JunB translation via mTOR signaling.
Staber PB; Vesely P; Haq N; Ott RG; Funato K; Bambach I; Fuchs C; Schauer S; Linkesch W; Hrzenjak A; Dirks WG; Sexl V; Bergler H; Kadin ME; Sternberg DW; Kenner L; Hoefler G
Blood; 2007 Nov; 110(9):3374-83. PubMed ID: 17690253
[TBL] [Abstract][Full Text] [Related]
4. The expression of CD30 in anaplastic large cell lymphoma is regulated by nucleophosmin-anaplastic lymphoma kinase-mediated JunB level in a cell type-specific manner.
Hsu FY; Johnston PB; Burke KA; Zhao Y
Cancer Res; 2006 Sep; 66(18):9002-8. PubMed ID: 16982741
[TBL] [Abstract][Full Text] [Related]
5. Expression of granzyme B sensitizes ALK+ ALCL tumour cells to apoptosis-inducing drugs.
Pearson JD; Zhang J; Wu Z; Thew KD; Rowe KJ; Bacani JT; Ingham RJ
Mol Cancer; 2014 Aug; 13():199. PubMed ID: 25168906
[TBL] [Abstract][Full Text] [Related]
6. Nucleophosmin-anaplastic lymphoma kinase: the ultimate oncogene and therapeutic target.
Werner MT; Zhao C; Zhang Q; Wasik MA
Blood; 2017 Feb; 129(7):823-831. PubMed ID: 27879258
[TBL] [Abstract][Full Text] [Related]
7. Constitutive control of AKT1 gene expression by JUNB/CJUN in ALK+ anaplastic large-cell lymphoma: a novel crosstalk mechanism.
Atsaves V; Zhang R; Ruder D; Pan Y; Leventaki V; Rassidakis GZ; Claret FX
Leukemia; 2015 Nov; 29(11):2162-72. PubMed ID: 25987255
[TBL] [Abstract][Full Text] [Related]
8. Silibinin suppresses NPM-ALK, potently induces apoptosis and enhances chemosensitivity in ALK-positive anaplastic large cell lymphoma.
Molavi O; Samadi N; Wu C; Lavasanifar A; Lai R
Leuk Lymphoma; 2016 May; 57(5):1154-62. PubMed ID: 26133723
[TBL] [Abstract][Full Text] [Related]
9. Molecular characterization of the t(2;5) (p23; q35) translocation in anaplastic large cell lymphoma (Ki-1) and Hodgkin's disease.
Yee HT; Ponzoni M; Merson A; Goldstein M; Scarpa A; Chilosi M; Menestrina F; Pittaluga S; de Wolf-Peeters C; Shiota M; Mori S; Frizzera G; Inghirami G
Blood; 1996 Feb; 87(3):1081-8. PubMed ID: 8562933
[TBL] [Abstract][Full Text] [Related]
10. STAT1 is phosphorylated and downregulated by the oncogenic tyrosine kinase NPM-ALK in ALK-positive anaplastic large-cell lymphoma.
Wu C; Molavi O; Zhang H; Gupta N; Alshareef A; Bone KM; Gopal K; Wu F; Lewis JT; Douglas DN; Kneteman NM; Lai R
Blood; 2015 Jul; 126(3):336-45. PubMed ID: 25921060
[TBL] [Abstract][Full Text] [Related]
11. PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas.
Laimer D; Dolznig H; Kollmann K; Vesely PW; Schlederer M; Merkel O; Schiefer AI; Hassler MR; Heider S; Amenitsch L; Thallinger C; Staber PB; Simonitsch-Klupp I; Artaker M; Lagger S; Turner SD; Pileri S; Piccaluga PP; Valent P; Messana K; Landra I; Weichhart T; Knapp S; Shehata M; Todaro M; Sexl V; Höfler G; Piva R; Medico E; Ruggeri BA; Cheng M; Eferl R; Egger G; Penninger JM; Jaeger U; Moriggl R; Inghirami G; Kenner L
Nat Med; 2012 Nov; 18(11):1699-704. PubMed ID: 23064464
[TBL] [Abstract][Full Text] [Related]
12. Analysis of gene expression profile of TPM3-ALK positive anaplastic large cell lymphoma reveals overlapping and unique patterns with that of NPM-ALK positive anaplastic large cell lymphoma.
Bohling SD; Jenson SD; Crockett DK; Schumacher JA; Elenitoba-Johnson KS; Lim MS
Leuk Res; 2008 Mar; 32(3):383-93. PubMed ID: 17720243
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance and therapeutic potential of the activation of anaplastic lymphoma kinase/protein kinase B/mammalian target of rapamycin signaling pathway in anaplastic large cell lymphoma.
Gao J; Yin M; Zhu Y; Gu L; Zhang Y; Li Q; Jia C; Ma Z
BMC Cancer; 2013 Oct; 13():471. PubMed ID: 24112608
[TBL] [Abstract][Full Text] [Related]
14. Involvement of Grb2 adaptor protein in nucleophosmin-anaplastic lymphoma kinase (NPM-ALK)-mediated signaling and anaplastic large cell lymphoma growth.
Riera L; Lasorsa E; Ambrogio C; Surrenti N; Voena C; Chiarle R
J Biol Chem; 2010 Aug; 285(34):26441-50. PubMed ID: 20554525
[TBL] [Abstract][Full Text] [Related]
15. Transcripts of the npm-alk fusion gene in anaplastic large cell lymphoma, Hodgkin's disease, and reactive lymphoid lesions.
Elmberger PG; Lozano MD; Weisenburger DD; Sanger W; Chan WC
Blood; 1995 Nov; 86(9):3517-21. PubMed ID: 7579458
[TBL] [Abstract][Full Text] [Related]
16. The NPM-ALK and the ATIC-ALK fusion genes can be detected in non-neoplastic cells.
Maes B; Vanhentenrijk V; Wlodarska I; Cools J; Peeters B; Marynen P; de Wolf-Peeters C
Am J Pathol; 2001 Jun; 158(6):2185-93. PubMed ID: 11395396
[TBL] [Abstract][Full Text] [Related]
17. Lobatin B inhibits NPM/ALK and NF-κB attenuating anaplastic-large-cell-lymphomagenesis and lymphendothelial tumour intravasation.
Kiss I; Unger C; Huu CN; Atanasov AG; Kramer N; Chatruphonprasert W; Brenner S; McKinnon R; Peschel A; Vasas A; Lajter I; Kain R; Saiko P; Szekeres T; Kenner L; Hassler MR; Diaz R; Frisch R; Dirsch VM; Jäger W; de Martin R; Bochkov VN; Passreiter CM; Peter-Vörösmarty B; Mader RM; Grusch M; Dolznig H; Kopp B; Zupko I; Hohmann J; Krupitza G
Cancer Lett; 2015 Jan; 356(2 Pt B):994-1006. PubMed ID: 25444930
[TBL] [Abstract][Full Text] [Related]
18. Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas.
Drexler HG; Gignac SM; von Wasielewski R; Werner M; Dirks WG
Leukemia; 2000 Sep; 14(9):1533-59. PubMed ID: 10994999
[TBL] [Abstract][Full Text] [Related]
19. NPM-ALK oncogenic kinase promotes cell-cycle progression through activation of JNK/cJun signaling in anaplastic large-cell lymphoma.
Leventaki V; Drakos E; Medeiros LJ; Lim MS; Elenitoba-Johnson KS; Claret FX; Rassidakis GZ
Blood; 2007 Sep; 110(5):1621-30. PubMed ID: 17416736
[TBL] [Abstract][Full Text] [Related]
20. IGF-IR tyrosine kinase interacts with NPM-ALK oncogene to induce survival of T-cell ALK+ anaplastic large-cell lymphoma cells.
Shi P; Lai R; Lin Q; Iqbal AS; Young LC; Kwak LW; Ford RJ; Amin HM
Blood; 2009 Jul; 114(2):360-70. PubMed ID: 19423729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
